Healthcare - Biotechnology - NASDAQ - US
$ 1.18
-5.6 %
$ 63.8 M
Market Cap
3.47
P/E
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite.[ Read More ]
The intrinsic value of one SPRO stock under the base case scenario is HIDDEN Compared to the current market price of 1.18 USD, Spero Therapeutics, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart SPRO
FINANCIALS
96.7 M
REVENUE
21.5 M
OPERATING INCOME
22.8 M
NET INCOME
-33 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
221 K
FINANCING CASH FLOW
13.5 M
REVENUE
-18.6 M
OPERATING INCOME
-17.1 M
NET INCOME
12.8 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
0
FINANCING CASH FLOW
Balance Sheet Decomposition
Spero Therapeutics, Inc.
| Current Assets | 131 M |
| Cash & Short-Term Investments | 76.3 M |
| Receivables | 50.7 M |
| Other Current Assets | 4.18 M |
| Non-Current Assets | 51.2 M |
| Long-Term Investments | 0 |
| PP&E | 4.16 M |
| Other Non-Current Assets | 47 M |
| Current Liabilities | 37.2 M |
| Accounts Payable | 1.38 M |
| Short-Term Debt | 3.44 M |
| Other Current Liabilities | 32.3 M |
| Non-Current Liabilities | 38.3 M |
| Long-Term Debt | 3.82 M |
| Other Non-Current Liabilities | 34.5 M |
EFFICIENCY
Earnings Waterfall
Spero Therapeutics, Inc.
| Revenue | 96.7 M |
| Cost Of Revenue | 367 K |
| Gross Profit | 96.4 M |
| Operating Expenses | 75.3 M |
| Operating Income | 21.5 M |
| Other Expenses | -1.32 M |
| Net Income | 22.8 M |
RATIOS
99.62%
GROSS MARGIN
22.21%
OPERATING MARGIN
23.58%
NET MARGIN
21.34%
ROE
12.50%
ROA
17.76%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Spero Therapeutics, Inc.
| Net Income | 22.8 M |
| Depreciation & Amortization | 367 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 7.93 M |
| Change in Working Capital | -70.4 M |
| Others | -64.9 M |
| Free Cash Flow | -33 M |
Wall Street Analysts Price Targets
Spero Therapeutics, Inc.
SPRO has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0.015 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Spero Therapeutics, Inc.
Sold
0-3 MONTHS
67.7 K USD 4
3-6 MONTHS
42.6 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
318 K USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 week ago
Nov 07, 2024
|
Sell 30.6 K USD
|
Rajavelu Esther
CFO & CBO |
- 23351
|
1.31 USD |
|
1 week ago
Nov 08, 2024
|
Sell 22.4 K USD
|
Rajavelu Esther
CFO & CBO |
- 17245
|
1.3 USD |
|
2 months ago
Aug 27, 2024
|
Sell 7.98 K USD
|
Mahadevia Ankit
Director |
- 5912
|
1.35 USD |
|
2 months ago
Aug 27, 2024
|
Sell 2.99 K USD
|
Keutzer Timothy
Chief Operating Officer |
- 2213
|
1.35 USD |
|
2 months ago
Aug 27, 2024
|
Sell 3.72 K USD
|
Shukla Sath
CEO & President |
- 2757
|
1.35 USD |
|
3 months ago
Aug 02, 2024
|
Sell 19.5 K USD
|
Shukla Sath
CEO and President |
- 14800
|
1.32 USD |
|
3 months ago
Aug 05, 2024
|
Sell 23.1 K USD
|
Shukla Sath
CEO and President |
- 17641
|
1.31 USD |
|
9 months ago
Feb 02, 2024
|
Sell 42.1 K USD
|
Keutzer Timothy
Chief Operating Officer |
- 30971
|
1.36 USD |
|
9 months ago
Feb 02, 2024
|
Sell 87.4 K USD
|
Mahadevia Ankit
Director |
- 63795
|
1.37 USD |
|
9 months ago
Feb 02, 2024
|
Sell 42.3 K USD
|
JOSEPH TAMARA L
Chief Legal Officer |
- 30906
|
1.37 USD |
|
9 months ago
Feb 02, 2024
|
Sell 38.5 K USD
|
HAMED KAMAL
Chief Medical Officer |
- 28075
|
1.37 USD |
|
9 months ago
Feb 02, 2024
|
Sell 42.3 K USD
|
Shukla Sath
CEO and President |
- 30901
|
1.37 USD |
|
9 months ago
Feb 05, 2024
|
Sell 65.4 K USD
|
Shukla Sath
CEO and President |
- 45093
|
1.45 USD |
|
1 year ago
Sep 13, 2023
|
Sell 50.2 K USD
|
HAMED KAMAL
Chief Medical Officer |
- 39496
|
1.27 USD |
|
1 year ago
Aug 28, 2023
|
Sell 2.34 K USD
|
Keutzer Timothy
Chief Development Officer |
- 1854
|
1.26 USD |
|
1 year ago
Aug 28, 2023
|
Sell 2.34 K USD
|
JOSEPH TAMARA L
Chief Legal Officer |
- 1854
|
1.26 USD |
|
1 year ago
Aug 28, 2023
|
Sell 11.4 K USD
|
Mahadevia Ankit
Director |
- 9040
|
1.26 USD |
|
1 year ago
Aug 28, 2023
|
Sell 2.34 K USD
|
Shukla Sath
CEO and President |
- 1854
|
1.26 USD |
|
1 year ago
Aug 29, 2023
|
Sell 5.41 K USD
|
Shukla Sath
CEO and President |
- 4163
|
1.3 USD |
|
1 year ago
Feb 03, 2023
|
Sell 22.2 K USD
|
Mahadevia Ankit
CEO and President |
- 12286
|
1.81 USD |
|
1 year ago
Feb 02, 2023
|
Sell 6.31 K USD
|
Keutzer Timothy
Chief Operating Officer |
- 3394
|
1.86 USD |
|
1 year ago
Feb 02, 2023
|
Sell 6.31 K USD
|
JOSEPH TAMARA L
Chief Legal Officer |
- 3394
|
1.86 USD |
|
1 year ago
Feb 02, 2023
|
Sell 17.4 K USD
|
Shukla Sath
Chief Financial Officer |
- 9504
|
1.8279 USD |
|
2 years ago
Sep 22, 2022
|
Sell 3.01 M USD
|
Aquilo Capital Management, LLC
10 percent owner |
- 1335512
|
2.2503 USD |
|
2 years ago
Sep 22, 2022
|
Sell 1.27 M USD
|
Aquilo Capital Management, LLC
10 percent owner |
- 566284
|
2.2503 USD |
|
2 years ago
Aug 29, 2022
|
Sell 5.38 K USD
|
Shukla Sath
Chief Financial Officer |
- 6017
|
0.8938 USD |
|
2 years ago
Apr 26, 2022
|
Bought 208 K USD
|
Aquilo Capital, L.P.
director: |
+ 39727
|
5.235 USD |
|
2 years ago
Apr 26, 2022
|
Bought 208 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 39727
|
5.235 USD |
|
2 years ago
Mar 30, 2022
|
Bought 148 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 16885
|
8.7884 USD |
|
2 years ago
Mar 30, 2022
|
Bought 291 K USD
|
Aquilo Capital, L.P.
director: |
+ 33115
|
8.7884 USD |
|
2 years ago
Mar 30, 2022
|
Bought 291 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 33115
|
8.7884 USD |
|
2 years ago
Mar 14, 2022
|
Bought 61.1 K USD
|
Aquilo Capital, L.P.
director: |
+ 8006
|
7.626 USD |
|
2 years ago
Mar 14, 2022
|
Bought 61.1 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 8006
|
7.626 USD |
|
2 years ago
Mar 14, 2022
|
Bought 120 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 15702
|
7.626 USD |
|
2 years ago
Feb 28, 2022
|
Bought 144 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 15104
|
9.5293 USD |
|
2 years ago
Feb 28, 2022
|
Bought 283 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 29729
|
9.5293 USD |
|
2 years ago
Feb 18, 2022
|
Bought 137 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 14828
|
9.2419 USD |
|
2 years ago
Jan 31, 2022
|
Bought 1.45 M USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 125000
|
11.5861 USD |
|
2 years ago
Jan 24, 2022
|
Bought 17.4 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 1599
|
10.8931 USD |
|
2 years ago
Jan 18, 2022
|
Bought 602 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 48488
|
12.4147 USD |
|
2 years ago
Jan 10, 2022
|
Bought 115 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 8867
|
12.9253 USD |
|
2 years ago
Dec 31, 2021
|
Bought 1.97 M USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 125000
|
15.7522 USD |
|
2 years ago
Dec 30, 2021
|
Bought 789 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 50000
|
15.7722 USD |
|
2 years ago
Dec 29, 2021
|
Bought 1.11 M USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 75493
|
14.6406 USD |
|
2 years ago
Dec 27, 2021
|
Sell 117 K USD
|
Mahadevia Ankit
CEO and President |
- 8000
|
14.5833 USD |
|
3 years ago
Oct 29, 2021
|
Bought 2.63 M USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 150000
|
17.5345 USD |
|
3 years ago
Sep 30, 2021
|
Bought 2.51 M USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 134543
|
18.6496 USD |
|
3 years ago
Sep 14, 2021
|
Bought 39.9 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 2156
|
18.4937 USD |
|
3 years ago
Sep 13, 2021
|
Bought 821 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 44210
|
18.5631 USD |
|
3 years ago
Sep 09, 2021
|
Bought 458 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 24749
|
18.4974 USD |
|
3 years ago
Aug 31, 2021
|
Bought 921 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 48645
|
18.9261 USD |
|
3 years ago
Aug 30, 2021
|
Bought 787 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 44042
|
17.8661 USD |
|
3 years ago
Aug 27, 2021
|
Bought 236 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 13957
|
16.8755 USD |
|
3 years ago
Aug 26, 2021
|
Bought 380 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 22982
|
16.5487 USD |
|
3 years ago
Aug 24, 2021
|
Bought 654 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 40170
|
16.2757 USD |
|
3 years ago
Aug 23, 2021
|
Bought 2.25 M USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 137835
|
16.3336 USD |
|
3 years ago
Aug 20, 2021
|
Bought 3.29 M USD
|
Aquilo Capital Management, LLC
10 percent owner |
+ 221190
|
14.8601 USD |
|
3 years ago
Feb 08, 2021
|
Sell 65.2 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
- 3000
|
21.7384 USD |
|
3 years ago
Feb 01, 2021
|
Sell 263 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
- 13661
|
19.2417 USD |
|
3 years ago
Feb 02, 2021
|
Sell 434 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
- 22841
|
18.9909 USD |
|
3 years ago
Feb 03, 2021
|
Sell 557 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
- 29354
|
18.9787 USD |
|
3 years ago
Feb 04, 2021
|
Sell 648 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
- 34144
|
18.9859 USD |
|
3 years ago
Dec 16, 2020
|
Sell 278 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
- 14933
|
18.6188 USD |
|
3 years ago
Dec 17, 2020
|
Sell 4.7 M USD
|
Aquilo Capital Management, LLC
10 percent owner |
- 250000
|
18.8129 USD |
|
3 years ago
Dec 16, 2020
|
Sell 228 K USD
|
Larkin Cristina
Chief Operating Officer |
- 12000
|
19 USD |
|
4 years ago
Nov 09, 2020
|
Sell 1.73 M USD
|
Aquilo Capital Management, LLC
10 percent owner |
- 125900
|
13.7734 USD |
|
4 years ago
Nov 04, 2020
|
Sell 1.03 M USD
|
Aquilo Capital Management, LLC
10 percent owner |
- 72500
|
14.2585 USD |
|
4 years ago
Nov 05, 2020
|
Sell 1.35 M USD
|
Aquilo Capital Management, LLC
10 percent owner |
- 96600
|
13.9786 USD |
|
4 years ago
Nov 06, 2020
|
Sell 68.9 K USD
|
Aquilo Capital Management, LLC
10 percent owner |
- 5000
|
13.7747 USD |
|
4 years ago
Nov 04, 2020
|
Sell 106 K USD
|
Mahadevia Ankit
CEO and President |
- 7370
|
14.4281 USD |
|
4 years ago
Nov 03, 2020
|
Sell 30.5 K USD
|
Mahadevia Ankit
CEO and President |
- 2137
|
14.2675 USD |
|
4 years ago
Oct 23, 2020
|
Sell 285 USD
|
Mahadevia Ankit
CEO and President |
- 20
|
14.25 USD |
|
4 years ago
Oct 14, 2020
|
Sell 1.5 K USD
|
Mahadevia Ankit
CEO and President |
- 105
|
14.25 USD |
|
4 years ago
Oct 13, 2020
|
Sell 205 K USD
|
Mahadevia Ankit
CEO and President |
- 14367
|
14.2836 USD |
|
4 years ago
Sep 08, 2020
|
Sell 11 K USD
|
Mahadevia Ankit
CEO and President |
- 774
|
14.2503 USD |
|
4 years ago
Jul 09, 2020
|
Sell 32.8 K USD
|
Mahadevia Ankit
CEO and President |
- 2293
|
14.3073 USD |
|
4 years ago
Jul 07, 2020
|
Sell 10.7 K USD
|
Mahadevia Ankit
CEO and President |
- 754
|
14.2506 USD |
|
4 years ago
Jun 23, 2020
|
Sell 115 K USD
|
Mahadevia Ankit
CEO and President |
- 8045
|
14.3274 USD |
|
4 years ago
Jun 25, 2020
|
Sell 37.7 K USD
|
Mahadevia Ankit
CEO and President |
- 2642
|
14.2507 USD |
|
4 years ago
Jun 22, 2020
|
Sell 37.4 K USD
|
Mahadevia Ankit
CEO and President |
- 2613
|
14.2996 USD |
|
4 years ago
Jun 24, 2020
|
Sell 55.4 K USD
|
Mahadevia Ankit
CEO and President |
- 3880
|
14.2834 USD |
|
6 years ago
Jul 17, 2018
|
Bought 1 M USD
|
GLAXOSMITHKLINE PLC
10 percent owner |
+ 80000
|
12.5 USD |
|
6 years ago
Jul 05, 2018
|
Sell 70 K USD
|
Larkin Cristina
Chief Operating Officer |
- 4000
|
17.5 USD |
|
6 years ago
Jul 05, 2018
|
Sell 35 K USD
|
Sendek Joel
Chief Financial Officer |
- 2000
|
17.5 USD |
|
6 years ago
Jul 06, 2018
|
Sell 8.75 K USD
|
Mahadevia Ankit
See Remarks |
- 500
|
17.5 USD |
|
6 years ago
Jul 06, 2018
|
Sell 1.75 K USD
|
Mahadevia Ankit
See Remarks |
- 100
|
17.545 USD |
|
6 years ago
Jul 06, 2018
|
Sell 7.03 K USD
|
Mahadevia Ankit
See Remarks |
- 400
|
17.58 USD |
|
6 years ago
Jul 06, 2018
|
Sell 1.76 K USD
|
Mahadevia Ankit
See Remarks |
- 100
|
17.62 USD |
|
6 years ago
Jul 06, 2018
|
Sell 1.77 K USD
|
Mahadevia Ankit
See Remarks |
- 100
|
17.705 USD |
|
6 years ago
Jul 06, 2018
|
Sell 3.58 K USD
|
Mahadevia Ankit
See Remarks |
- 200
|
17.9 USD |
|
6 years ago
Jul 06, 2018
|
Sell 3.58 K USD
|
Mahadevia Ankit
See Remarks |
- 200
|
17.92 USD |
|
6 years ago
Jul 05, 2018
|
Sell 54.2 K USD
|
Mahadevia Ankit
See Remarks |
- 3076
|
17.6215 USD |
|
7 years ago
Nov 06, 2017
|
Bought 6 M USD
|
GLAXOSMITHKLINE PLC
10 percent owner |
+ 428571
|
14 USD |
|
7 years ago
Nov 06, 2017
|
Bought 6 M USD
|
FORMELA JEAN FRANCOIS
Director |
+ 428571
|
14 USD |
|
7 years ago
Nov 06, 2017
|
Bought 6 M USD
|
Goyal Vikas
Director |
+ 428571
|
14 USD |
|
7 years ago
Nov 06, 2017
|
Bought 70 K USD
|
Sendek Joel
Chief Financial Officer |
+ 5000
|
14 USD |
|
7 years ago
Nov 06, 2017
|
Bought 21 K USD
|
Larkin Cristina
Chief Operating Officer |
+ 1500
|
14 USD |
|
7 years ago
Nov 06, 2017
|
Bought 3 M USD
|
Breum Casper
Director |
+ 214285
|
14 USD |
7. News
New Strong Buy Stocks for November 15th
FHI, RJF, ASTS, APLD and SPRO have been added to the Zacks Rank #1 (Strong Buy) List on November 15, 2024.
zacks.com
- 1 day ago
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates
Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to earnings of $0.02 per share a year ago.
zacks.com
- 2 days ago
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update
Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the third quarter ended September 30, 2024, and provided a business update.
globenewswire.com
- 2 days ago
Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024
In vitro data on SPR719 show low propensity for resistance development in NTM-PD MAC strains when administered as a single agent and in combination with standard of care agents
globenewswire.com
- 1 month ago
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy
Phase 1 study showed significant lung uptake and enhanced epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of SPR719 (active moiety of SPR720) Phase 1 study showed significant lung uptake and enhanced epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of SPR719 (active moiety of SPR720)
globenewswire.com
- 1 month ago
Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript
Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 AM ET Company Participants Shai Biran - Senior Director Investor Relations Sath Shukla - Chief Executive Officer Esther Rajavelu - CFO and Chief Business Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Gavin Clark-Gartner - Evercore ISI Ritu Baral - TD Cowen Operator Good afternoon and welcome to the Spero Therapeutics Second Quarter 2024 Financial Results Conference Call. At this time all participants are in listen-only mode.
seekingalpha.com
- 3 months ago
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.23 per share a year ago.
zacks.com
- 3 months ago
Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update
CAMBRIDGE, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the second quarter ended June 30, 2024, and provided a business update.
globenewswire.com
- 3 months ago
Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024
CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Monday August 5th, 2024 at 4:30 p.m. ET to report financial results for second quarter 2024 and provide an update on its business and pipeline.
globenewswire.com
- 3 months ago
3 Micro-Cap Moonshots for Fearless Investors
When discussing micro-cap stocks, it's important to recognize their general overlap with the world of penny stocks. These stocks trade as shares of companies with market capitalizations between $50 million and $300 million.
investorplace.com
- 4 months ago
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on May 28, 2024, the Compensation Committee of Spero's Board of Directors approved the grant of an aggregate of 227,500 restricted stock unit awards (RSUs) to new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The RSUs are being granted as an inducement material to each of the new employees becoming an employee of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
globenewswire.com
- 4 months ago
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on May 28, 2024, the Compensation Committee of Spero's Board of Directors approved the grant of 116,667 restricted stock unit awards (RSUs) to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The RSUs are being granted as an inducement material to the new employee becoming an employee of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
globenewswire.com
- 5 months ago
8. Profile Summary
Spero Therapeutics, Inc. SPRO
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 63.8 M
Dividend Yield
0.00%
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Contact
675 Massachusetts Avenue, Cambridge, MA, 02139
https://sperotherapeutics.com
IPO Date
Nov. 2, 2017
Employees
46
Officers
Mr. Timothy Keutzer
Chief Operating Officer
Mr. James P. Brady
Chief Human Resource Officer
Mr. Satyavrat Shukla C.F.A.
President, Chief Executive Officer & Director
Ms. Esther P. Rajavelu
Chief Financial Officer, Chief Business Officer & Treasurer
Dr. Ankit Mahadevia M.D., MBA
Co-Founder & Chairman of the Board